title: Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein.
abstract: Mice vaccinated intraperitoneally (i.p.) with 10(7) p.f.u. of a vaccinia virus recombinant expressing either the glycoprotein (rVac-G) or nucleoprotein (rVac-N) of rabies virus 3 weeks before challenge were protected against peripheral lethal infection. Similarly, by post-exposure vaccination in which mice were first infected with rabies virus and subsequently vaccinated i.p. with the recombinant, rVac-G conferred protection when given immediately following infection and up to 24 h after infection. Prior treatment of those mice with anti-CD8 monoclonal antibodies (MAb) did not significantly affect the outcome of the infection. In contrast, rVac-N failed to confer protection even with higher doses (10(8) p.f.u.) of the virus or even when administered by the intradermal route. Anti-nucleoprotein antibody production by these mice was not suppressed by prior rabies virus infection and the levels and the time of antibody production were similar to those of anti-glycoprotein antibody production in mice vaccinated with rVac-G after rabies virus infection. The cytotoxic T lymphocyte response was also not down-regulated by rabies virus in the mice that were given rVac-N. Possible mechanism(s) for the ineffectiveness of rVac-N by post-exposure vaccination in contrast to pre-exposure vaccination was discussed.
authors.affiliation: Department of Microbiology, Oita Medical University, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Fujii
authors.forename: Y
authors.initials: Y
authors.lastname: Takita-Sonoda
authors.forename: K
authors.initials: K
authors.lastname: Mifune
authors.forename: K
authors.initials: K
authors.lastname: Hirai
authors.forename: A
authors.initials: A
authors.lastname: Nishizono
authors.forename: K
authors.initials: K
authors.lastname: Mannen
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D000917:Antibody Formation; D000956:Antigens, Viral; D016827:CD8 Antigens / Q000276:immunology; D002213:Capsid / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D006023:Glycoproteins / Q000276:immunology*; D007111:Immunity, Cellular; D051379:Mice; D008805:Mice, Inbred A; D011818:Rabies / Q000276:immunology / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000276:immunology; D014616:Vaccinia virus; D014758:Viral Core Proteins / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D016827:CD8 Antigens; D006023:Glycoproteins; D011819:Rabies Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014758:Viral Core Proteins; D014759:Viral Envelope Proteins; C064951:glycoprotein G, Rabies virus